1
|
Altcheh J, Sierra V, Ramirez T, Pinto Rocha JJ, Grossmann U, Huang E, Moscatelli G, Ding O. Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE). Antimicrob Agents Chemother 2023; 67:e0119322. [PMID: 36975790 PMCID: PMC10112190 DOI: 10.1128/aac.01193-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023] Open
Abstract
Nifurtimox is recommended for the treatment of Chagas disease; however, long-term follow-up data are scarce. This prolonged follow-up phase of the prospective, historically controlled, CHICO clinical trial evaluated seronegative conversion in pediatric patients aged <18 years with Chagas disease who were followed for 4 years after nifurtimox treatment. Patients were randomly assigned 2:1 to nifurtimox 60-day or 30-day regimens comprising 10 to 20 mg/kg/day for patients aged <12 years and body weight <40 kg, and 8 to 10 mg/kg/day for those aged ≥12 years and body weight ≥40 kg. Anti-Trypanosoma cruzi antibodies decreased during the study period, achieving seronegative conversion in 16 (8.12%) and 8 (8.16%) patients in the 60-day and 30-day nifurtimox regimens, respectively, with corresponding incidence rates per 100 patients/year of seronegative conversion of 2.12 (95% confidence interval [CI]: 1.21 to 3.45) and 2.11 (95% CI: 0.91 to 4.16). Superiority of the 60-day nifurtimox regimen was confirmed by the lower limit of the 95% CI being higher than that (0%) in a historical placebo control group. Children aged <2 years at baseline were more likely to reach seronegative conversion during the 4-year follow-up than older children. At any annual follow-up visit, >90% of evaluable patients had persistently negative quantitative PCR results for T. cruzi DNA. No adverse events potentially related to treatment or caused by protocol-required procedures were documented for either treatment regimen. This study confirms the effectiveness and safety of a pediatric formulation of nifurtimox administered in an age- and weight-adjusted regimen for 60 days to treat children with Chagas disease.
Collapse
Affiliation(s)
- Jaime Altcheh
- Parasitología, Hospital de Niños Ricardo Gutiérrez and Instituto Multidisciplinario de Investigacion en Patologias Pediatricas (IMIPP), CONICET-GCBA, Buenos Aires, Argentina
| | - Victor Sierra
- Centro de Atención e Investigación Médica S.A., Yopal, Colombia
| | - Teresa Ramirez
- Centro de Enfermedad de Chagas y Patologias Regionales, Santiago del Estero, Argentina
| | - Jimy José Pinto Rocha
- Fundación CEADES-Plataforma de Atención Integral a los Pacientes con Enfermedades de Chagas, Cochabamba, Bolivia
| | - Ulrike Grossmann
- Bayer AG, Research and Development Pharmaceuticals, Berlin, Germany
| | | | - Guillermo Moscatelli
- Parasitología, Hospital de Niños Ricardo Gutiérrez and Instituto Multidisciplinario de Investigacion en Patologias Pediatricas (IMIPP), CONICET-GCBA, Buenos Aires, Argentina
| | | |
Collapse
|
2
|
Jaime ALTCHEH, Ramirez T, Sierra V, Moscatelli G, Dib J, Pinto J, Ortiz L, Falaschi A. 2128. Lack of Congenital Transmission in Infants Born of Female Patients with Chagas Disease who Became Pregnant During a Nifurtimox Study (CHICO and CHICO SECURE Study). Open Forum Infect Dis 2022. [PMCID: PMC9752953 DOI: 10.1093/ofid/ofac492.1749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Background There is some concern about the safety of nifurtimox (NF) for the offspring of treated women. Potential genotoxicity of NF was reported in in vitro models. However, the evidence to support the risks in fetal development is lacking for humans. In addition, a preventative effect over transplacental transmission was reported in girls and women with T.cruzi infection treated before pregnancy (mainly with benznidazole). Methods A multicenter, randomized, double-blind phase 3 clinical trial (NCT02625974) was set up to evaluate safety and efficacy of NF. A total of 330 patients, younger 18 years old, were enrolled, 67 were females of child-bearing age. The enrolled females of childbearing age agreed to use an effective method of contraception until 3 months after the last administration of NF. Pregnancy tests were performed at screening, during treatment and 30 days after end of treatment. Results No pregnancies were reported during treatment period. There were 5 pregnancies reported during the 1st year of post-treatment follow-up and another 21 pregnancies during the additional 3-year follow-up period. Two mothers did not consent to have their babies tested for T cruzi infection, and in one case an abortion was reported. Two women gave birth twice. There was information about transplacental transmission available in 18 babies. All mothers were T.cruzi RT-PCR negative at the end of the treatment period and remained negative during follow up. All newborns were live, healthy full-term and of weight appropriate for their gestational age, and had no perinatal complications except one baby who was healthy but small for gestational age. T.cruzi infection was ruled out by a negative direct parasitological test during the first days of life in 12 infants , and /or by ELISA T.cruzi serology at 8 -12 months of age in 14 infants, which was negative in all cases. Conclusion Our results showed that treatment of females on childbearing age with nifurtimox may prevent transplacental transmission of CD as was reported previously for benznidazole. Disclosures Jaime ALTCHEH, Sr., MD,PhD, Bayer: Advisor/Consultant.
Collapse
Affiliation(s)
- A L T C H E H Jaime
- Hospital de Niños R. Gutierrez, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
| | - Teresa Ramirez
- Centro de Chagas, Hospital Independencia, Santiago del Estero, Santiago del Estero, Argentina
| | - Victor Sierra
- CAIMED, PI, Bogota, Distrito Capital de Bogota, Colombia
| | - Guillermo Moscatelli
- Hospital de Niños R. Gutierrez, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
| | - Juan Dib
- Fundación Salud Para el Trópico, Santa Marta, Casanare, Colombia
| | - Jimy Pinto
- CEADES, Cochabamba, Cochabamba, Cochabamba, Bolivia
| | | | | |
Collapse
|
3
|
Biswal S, Borja-Tabora C, Martinez Vargas L, Velásquez H, Theresa Alera M, Sierra V, Johana Rodriguez-Arenales E, Yu D, Wickramasinghe VP, Duarte Moreira E, Fernando AD, Gunasekera D, Kosalaraksa P, Espinoza F, López-Medina E, Bravo L, Tuboi S, Hutagalung Y, Garbes P, Escudero I, Rauscher M, Bizjajeva S, LeFevre I, Borkowski A, Saez-Llorens X, Wallace D. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet 2020; 395:1423-1433. [PMID: 32197105 DOI: 10.1016/s0140-6736(20)30414-1] [Citation(s) in RCA: 110] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 02/10/2020] [Accepted: 02/11/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4-16 years. METHODS We present data up to 18 months post-vaccination from an ongoing phase 3, randomised, double-blind trial of TAK-003 in endemic regions of Asia and Latin America (26 medical and research centres across Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Philippines, Sri Lanka, and Thailand). Healthy children aged 4-16 years were randomly assigned 2:1 (stratified by age and region) to receive two doses of TAK-003 or two doses of placebo, 3 months apart. Investigators, participants and their parents or guardians, and sponsor representatives advising on trial conduct were masked to trial group assignments. Participants presenting with febrile illness were tested for virologically confirmed dengue (VCD) by serotype-specific RT-PCR. In timeframes beginning 30 days post-second dose, the primary endpoint (overall vaccine efficacy) was assessed in the first 11 months, and the secondary endpoints (efficacy by baseline serostatus, serotype, hospitalised dengue, and severe dengue) in the first 17 months. This study is registered with ClinicalTrials.gov, NCT02747927. FINDINGS 20 099 participants were randomly assigned and vaccinated between Sept 7, 2016, and Aug 18, 2017; 19 021 (94·6%) were included in the per protocol analysis, and 20 071 (99·9%) in the safety set. The primary endpoint was achieved with an overall vaccine efficacy of 80·2% (95% CI 73·3 to 85·3; 61 cases of VCD in the TAK-003 group vs 149 cases of VCD in the placebo group). In the secondary endpoint assessment timeframe, an overall vaccine efficacy of 73·3% (95% CI 66·5 to 78·8) was observed. Analysis of secondary endpoints showed efficacies of 76·1% (95% CI 68·5 to 81·9) in individuals who were seropositive at baseline, 66·2% (49·1 to 77·5) in individuals who were seronegative at baseline, 90·4% (82·6 to 94·7) against hospitalised dengue, and 85·9% (31·9 to 97·1) against dengue haemorrhagic fever. Efficacy varied by individual serotypes (DENV 1, 69·8% [95% CI 54·8 to 79·9]; DENV 2, 95·1% [89·9 to 97·6]; DENV 3, 48·9% [27·2 to 64·1]; DENV 4, 51·0% [-69·4 to 85·8]). Cumulative rates of serious adverse events were similar in TAK-003 (4·0%) and placebo (4·8%) recipients, and were consistent with expected medical disorders in the study population. Infection was the most frequent reason leading to serious adverse events. 20 participants (<0·1% of the safety set) were withdrawn from the trial due to 21 adverse events by the end of part two; 14 of these participants received TAK-003 and six received placebo. INTERPRETATION TAK-003 was well tolerated and efficacious against symptomatic dengue in children regardless of serostatus before immunisation. Vaccine efficacy varied by serotype, warranting continued follow-up to assess longer-term vaccine performance. FUNDING Takeda Vaccines.
Collapse
Affiliation(s)
| | | | - Luis Martinez Vargas
- Centro de Atención e Investigación Médica, Dominicana, Santo Domingo, Dominican Republic
| | | | - Maria Theresa Alera
- Philippines-Armed Forces Research Institute of Medical Sciences Virology Research Unit, Cebu City, Philippines
| | - Victor Sierra
- Centro de Atención e Investigación Médica, Yopal, Colombia
| | | | - Delia Yu
- De La Salle Medical and Health Sciences Institute, Dasmariñas, Philippines
| | | | - Edson Duarte Moreira
- Associação Obras Sociais Irmã Dulce Hospital Santo Antônio and Oswaldo Cruz Foundation, Bahia, Brazil
| | | | - Dulanie Gunasekera
- Faculty of Medical Sciences, University of Sri Jayawardenenpura, Gangodawila, Sri Lanka
| | | | - Felix Espinoza
- National Autonomous University of Nicaragua, León, Nicaragua
| | - Eduardo López-Medina
- Centro de Estudios en Infectología Pediátrica, Universidad del Valle and Centro Médico Imbanaco, Cali, Colombia
| | - Lulu Bravo
- University of the Philippines Manila, Ermita, Philippines
| | | | | | | | | | | | | | - Inge LeFevre
- Takeda Pharmaceuticals International, Zurich, Switzerland
| | | | - Xavier Saez-Llorens
- Hospital del Niño Dr José Renán Esquivel, Sistema Nacional de Investigación at Secretaría Nacional de Ciencia y Tecnología, Centro de Vacunación Internacional (Cevaxin), Panama City, Panama
| | | |
Collapse
|
4
|
Díaz F, Díaz-Luis A, Sierra V, Diñeiro Y, González P, García-Torres S, Tejerina D, Romero-Fernández M, Cabeza de Vaca M, Coto-Montes A, Oliván M. What functional proteomic and biochemical analysis tell us about animal stress in beef? J Proteomics 2020; 218:103722. [DOI: 10.1016/j.jprot.2020.103722] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Revised: 02/23/2020] [Accepted: 02/24/2020] [Indexed: 12/18/2022]
|
5
|
Sierra V, Fernández-Suárez V, Castro P, Osoro K, Rodríguez-Colunga M, Vega-Naredo I, García- Macía M, Coto-Montes A, Oliván M. Tenderización post-mortem de la carne de los distintos biotipos amparados por la IGP Ternera Asturiana. Arch zootec 2011. [DOI: 10.4321/s0004-05922011000300004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
6
|
Soria-Valles C, Caballero B, Vega-Naredo I, Sierra V, Huidobro-Fernández C, Gonzalo-Calvo DD, Tolivia D, Rodríguez-Colunga MJ, Joel A, Coto-Montes A, Avivi A. Antioxidant responses to variations of oxygen by the Harderian gland of different species of the superspecies Spalax ehrenbergi. CAN J ZOOL 2010. [DOI: 10.1139/z10-049] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The subterranean blind mole rats of the superspecies Spalax ehrenbergi (Nehring, 1898) have developed several strategies to cope with changing concentrations of underground oxygen. Such an atmosphere induces the generation of reactive oxygen species that can cause oxidative damage without proper control. To understand how S. ehrenbergi appear to be able to counteract the free radicals and avoid oxidative damage, we studied the oxidative status of the Harderian gland (an organ particularly vulnerable to oxidative stress in many rodents) in two species of the superspecies S. ehrenbergi ( Spalax galili and Spalax judaei ) under different oxygen concentration levels, paying special attention to the antioxidant defences developed by these animals and the resulting macromolecular damage. The results presented herein reinforce the idea that S. ehrenbergi deal better with hypoxic conditions than other rodents by regulating the activity of its antioxidant enzymes. Moreover, S. galili is better adapted to hypoxic conditions, whereas S. judaei appears to be better adapted to hyperoxic conditions.
Collapse
Affiliation(s)
- C. Soria-Valles
- Department of Morphology and Cellular Biology, Faculty of Medicine, University of Oviedo, Oviedo (33006), Asturias, Spain
- Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA), Villaviciosa, Spain
- Laboratory of Animal Molecular Evolution, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
| | - B. Caballero
- Department of Morphology and Cellular Biology, Faculty of Medicine, University of Oviedo, Oviedo (33006), Asturias, Spain
- Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA), Villaviciosa, Spain
- Laboratory of Animal Molecular Evolution, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
| | - I. Vega-Naredo
- Department of Morphology and Cellular Biology, Faculty of Medicine, University of Oviedo, Oviedo (33006), Asturias, Spain
- Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA), Villaviciosa, Spain
- Laboratory of Animal Molecular Evolution, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
| | - V. Sierra
- Department of Morphology and Cellular Biology, Faculty of Medicine, University of Oviedo, Oviedo (33006), Asturias, Spain
- Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA), Villaviciosa, Spain
- Laboratory of Animal Molecular Evolution, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
| | - C. Huidobro-Fernández
- Department of Morphology and Cellular Biology, Faculty of Medicine, University of Oviedo, Oviedo (33006), Asturias, Spain
- Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA), Villaviciosa, Spain
- Laboratory of Animal Molecular Evolution, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
| | - D. D. Gonzalo-Calvo
- Department of Morphology and Cellular Biology, Faculty of Medicine, University of Oviedo, Oviedo (33006), Asturias, Spain
- Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA), Villaviciosa, Spain
- Laboratory of Animal Molecular Evolution, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
| | - D. Tolivia
- Department of Morphology and Cellular Biology, Faculty of Medicine, University of Oviedo, Oviedo (33006), Asturias, Spain
- Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA), Villaviciosa, Spain
- Laboratory of Animal Molecular Evolution, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
| | - M. J. Rodríguez-Colunga
- Department of Morphology and Cellular Biology, Faculty of Medicine, University of Oviedo, Oviedo (33006), Asturias, Spain
- Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA), Villaviciosa, Spain
- Laboratory of Animal Molecular Evolution, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
| | - A. Joel
- Department of Morphology and Cellular Biology, Faculty of Medicine, University of Oviedo, Oviedo (33006), Asturias, Spain
- Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA), Villaviciosa, Spain
- Laboratory of Animal Molecular Evolution, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
| | - A. Coto-Montes
- Department of Morphology and Cellular Biology, Faculty of Medicine, University of Oviedo, Oviedo (33006), Asturias, Spain
- Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA), Villaviciosa, Spain
- Laboratory of Animal Molecular Evolution, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
| | - A. Avivi
- Department of Morphology and Cellular Biology, Faculty of Medicine, University of Oviedo, Oviedo (33006), Asturias, Spain
- Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA), Villaviciosa, Spain
- Laboratory of Animal Molecular Evolution, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
| |
Collapse
|
7
|
Coto-Montes A, Tomas-Zapico C, Martinez-Fraga J, Vega-Naredo I, Sierra V, Caballero B, Huidobro-Fernandez C, Soria-Valles C, Tolivia D, Rodriguez-Colunga MJ. Sexual Autophagic Differences in the Androgen-Dependent Flank Organ of Syrian Hamsters. ACTA ACUST UNITED AC 2008; 30:113-21. [DOI: 10.2164/jandrol.108.005355] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
8
|
Diez‐Pinol M, Dolan S, Sierra V, Cannings K. Personal and organizational determinants of well‐being at work. Int J Health Care Qual Assur 2008; 21:598-610. [DOI: 10.1108/09526860810900754] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Sierra V, Aldai N, Castro P, Osoro K, Coto-Montes A, Oliván M. Prediction of the fatty acid composition of beef by near infrared transmittance spectroscopy. Meat Sci 2008; 78:248-55. [DOI: 10.1016/j.meatsci.2007.06.006] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2007] [Revised: 06/07/2007] [Accepted: 06/16/2007] [Indexed: 11/15/2022]
|
10
|
Abstract
Our objective was to evaluate the role of vanadate on calcium extrusion in Fura-2-loaded rat pancreatic acinar cells by digital microscopic fluorimetry and spectrofluorimetry. In the absence of extracellular calcium, perfusion of pancreatic acinar cells with 1 nM CCK-8 and 1 mM vanadate did not significantly affect the typical transient calcium spike induced by CCK-8, but the plateau phase of calcium in response to CCK-8 remained elevated. In addition, vanadate was able to inhibit calcium efflux evoked by CCK-8 when we determined directly calcium transport across plasma membrane using Calcium Green-5N hexapotassium salt (cell impermeant form) in cell populations. The effect of vanadate on calcium extrusion was strongly blocked by the sulfhydryl-reducing agent dithiothreitol (DTT). The present results demonstrate that vanadate is able to irreversibly inhibit the calcium extrusion. This effect of vanadate can be blocked using DTT, indicating that its action is probably mediated by oxidation of sulfhydryl groups of Ca2+-ATPases.
Collapse
Affiliation(s)
- A I Lajas
- Department of Physiology. Faculty of Veterinary Science, University of Extremadura, PO Box 643, 10071, Cáceres, Spain.
| | | | | | | | | |
Collapse
|
11
|
Gallagher WM, Greene LM, Ryan MP, Sierra V, Berger A, Laurent-Puig P, Conseiller E. Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. FEBS Lett 2001; 489:59-66. [PMID: 11231014 DOI: 10.1016/s0014-5793(00)02389-9] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Here, we report the identification of a human orthologue of fibulin-4, along with analysis of its biosynthetic processing and mRNA expression levels in normal and tumour tissues. Comparative sequence analysis of fibulin-4 cDNAs revealed apparent polymorphisms in the signal sequence that could account for previously reported inefficient secretion in fibulin-4 transfectants. In vitro translation of fibulin-4 mRNA revealed the presence of full-length and truncated polypeptides, the latter apparently generated from an alternative translation initiation site. Since this polypeptide failed to incorporate into endoplasmic reticulum membrane preparations, it was concluded that it lacked a signal sequence and thus could represent an intracellular form of fibulin-4. Using fluorescence in situ hybridisation analysis, the human fibulin-4 gene was localised to chromosome 11q13, this region being syntenic to portions of mouse chromosomes 7 and 19. Considering the fact that translocations, amplifications and other rearrangements of the 11q13 region are associated with a variety of human cancers, the expression of human fibulin-4 was evaluated in a series of colon tumours. Reverse transcription-polymerase chain reaction analysis of RNA from paired human colon tumour and adjacent normal tissue biopsies showed that a significant proportion of tumours had approximately 2-7-fold increases in the level of fibulin-4 mRNA expression. Taken together, results reported here suggest that an intracellular form of fibulin-4 protein may exist and that dysregulated expression of the fibulin-4 gene is associated with human colon tumourigenesis.
Collapse
Affiliation(s)
- W M Gallagher
- Conway Institute of Biomolecular and Biomedical Research, Department of Pharmacology, University College Dublin, Belfield, Ireland.
| | | | | | | | | | | | | |
Collapse
|
12
|
Gallagher WM, Argentini M, Sierra V, Bracco L, Debussche L, Conseiller E. MBP1: a novel mutant p53-specific protein partner with oncogenic properties. Oncogene 1999; 18:3608-16. [PMID: 10380882 DOI: 10.1038/sj.onc.1202937] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Using a yeast two-hybrid screening strategy with a common tumour-derived p53 mutant as bait, we identified several mutant p53-interacting partners including the known proteins wild-type (wt) p53, hUBC9 and GBP/PIAS1. In addition, a novel protein partner was identified which we have termed MBP1, for Mutant p53-Binding Protein 1. MBP1 is a new member of the emerging fibulin gene family, which currently comprises fibulin-1, fibulin-2 and S1-5. Expression of MBP1 mRNA is differentially regulated both temporally during development of the mouse embryo and in a tissue-specific manner within the adult. Specific interaction between MBP1 and mutant p53 was illustrated by both two-hybrid analysis in yeast and co-immunoprecipitation in mammalian cells. MBP1 displayed the following order of binding specificity towards different p53 forms: H175 > G281 > H273 > or = W248>wt p53. Thus, MBP1 appears to bind preferentially to p53 mutants of the 'structural' rather than 'contact' class, reflecting a potential bias towards those mutants having a significant alteration in conformation from that assumed by wt p53. We propose that MBP1 is the product of a candidate oncogene as rates of both neoplastic transformation and tumour cell growth were shown to be significantly enhanced when the protein is ectopically overexpressed. Furthermore, MBP1 may play a role in determining if a 'gain of function' effect is seen with certain p53 mutants.
Collapse
Affiliation(s)
- W M Gallagher
- Oncology Department, Rhône-Poulenc Rorer, CRVA, Vitry-sur-Seine, France
| | | | | | | | | | | |
Collapse
|
13
|
Venot C, Maratrat M, Sierra V, Conseiller E, Debussche L. Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains. Oncogene 1999; 18:2405-10. [PMID: 10327062 DOI: 10.1038/sj.onc.1202539] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The wild-type protein product of the p53 tumor suppressor gene can activate transcription of genes which are involved in mediating either growth arrest, e.g. WAF1 or apoptotis, e.g. BAX and PICG3. Additionally, p53 can repress a variety of promoters, which, in turn, may be responsible for the functional activities exhibited by p53. This study shows that the Q22, S23 double mutation, which is known to inactivate a p53 transactivation subdomain located within the initial 40 residues of the protein, while abrogating transactivation from the WAF1 promoter, only attenuates apoptosis triggering, transactivation from other p53-responsive promoters and repression of promoters by p53. The Q53, S54 double mutation, which inactivates another p53 transactivation subdomain situated between amino acids 43 and 73 results in attenuation of all of the aforementioned p53 activities. In contrast to the Q22, S23 double mutation, this latter mutation set does not alter mdm-2-mediated inhibition and degradation of p53. Finally, mutation of all four residues results in complete abrogation of every p53 activity mentioned above.
Collapse
Affiliation(s)
- C Venot
- Centre de Recherche de Vitry-Alfortville, Rhône-Poulenc Rorer, Vitry sur Seine, France
| | | | | | | | | |
Collapse
|
14
|
Conseiller E, Debussche L, Landais D, Venot C, Maratrat M, Sierra V, Tocque B, Bracco L. CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. J Clin Invest 1998; 101:120-7. [PMID: 9421473 PMCID: PMC508547 DOI: 10.1172/jci1140] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The clinical potential of the p53 tumor suppressor gene is being evaluated currently for gene therapy of cancer. We have built a variant of wild-type p53, chimeric tumor suppressor 1 (CTS1), in which we have replaced the domains that mediate its inactivation. CTS1 presents some very interesting properties: (a) enhanced transcriptional activity; (b) resistance to the inactivation by oncogenic forms of p53; (c) resistance to the inactivation by MDM2; (d) lower sensitivity to E6-induced degradation; (e) ability to suppress cell growth; and (f ) faster induction of apoptosis. Thus, CTS1 is an improved tumor suppressor and an alternative for the treatment of wild-type p53-resistant human tumors by gene therapy.
Collapse
Affiliation(s)
- E Conseiller
- Gene Medicine Department, Rhône-Poulenc Rorer SA, 94403 Vitry sur Seine Cedex, France
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
IL-4 and IL-6 are pleiotropic cytokines that can act independently or synergistically to regulate lymphocyte growth and differentiation. Both of these factors are produced by cultures of Th2 cells but it is uncertain whether they are secreted simultaneously by a single cell. We used a sensitive and specific ELIspot assay to identify individual cells spontaneously producing IL-4 or IL-6 under physiological conditions in vivo. The fraction of cells producing these two lymphokines was regulated concurrently in cloned Th2 cells but varied independently in the lymphoid organs of normal BALB/c mice. A sandwich ELIspot assay was developed to determine whether individual cells simultaneously produced both cytokines. Thirteen per cent of cells in the spleen and 25% of those in the bone marrow of 10-week-old BALB/c mice secreting either IL-4 or IL-6 concurrently produced both of these lymphokines. These observations establish a physiological mechanism by which the concurrent production of synergistic cytokines is regulated in a given micro-environment.
Collapse
Affiliation(s)
- A Shirai
- Section of Retroviral Immunology, CBER/FDA, Bethesda, MD 20892
| | | | | | | |
Collapse
|
16
|
Candido J, Lutfy K, Billings B, Sierra V, Duttaroy A, Inturrisi CE, Yoburn BC. Effect of adrenal and sex hormones on opioid analgesia and opioid receptor regulation. Pharmacol Biochem Behav 1992; 42:685-92. [PMID: 1325057 DOI: 10.1016/0091-3057(92)90015-8] [Citation(s) in RCA: 84] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The role of endocrine factors on opioid analgesia (antinociception) and opioid receptors was studied in male and female Swiss-Webster mice. Morphine was more potent in male than in female mice, although this difference appears to be due to greater availability of morphine to the brain in males. Saturation binding studies indicated that the density and affinity of brain mu- and delta-opioid binding sites were equivalent in males and females. Males and females were implanted SC with naltrexone (NTX) or placebo pellets for 8 days, and then the pellets were removed. This treatment increased the density of mu and delta binding sites in brain and increased the potency of morphine for both sexes, although the increase in antinociceptive effects for males was greater than for females. Adrenalectomy (ADX) in male mice increased the potency of morphine and methadone but did not alter the brain levels of either drug. ADX did not alter brain opioid binding of either mu or delta ligands. When male ADX and control mice were treated with NTX, the potency of morphine and brain opioid binding sites were increased equivalently in both groups. Gonadectomy (GDX) in male mice tended to decrease morphine potency, although this was not found to be a very reliable effect. When male GDX and control mice were implanted with NTX, brain opioid binding was increased similarly in both groups, although morphine potency was increased less in GDX mice. Overall, these studies show that sex differences and hormones of the adrenals and gonads in male mice do not alter brain opioid receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J Candido
- Department of Pharmaceutical Sciences, College of Pharmacy, St. John's University, Queens, NY 11439
| | | | | | | | | | | | | |
Collapse
|
17
|
Sierra V, Duttaroy A, Lutfy K, Candido J, Billings B, Zito SW, Yoburn BC. Potentiation of opioid analgesia by cocaine: The role of spinal and supraspinal receptors. Life Sci 1992; 50:591-7. [PMID: 1346544 DOI: 10.1016/0024-3205(92)90371-u] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
These studies examined the effect of cocaine on the analgesia produced by systemically and centrally administered opioid agonists. Cocaine (50 mg/kg, s.c.) increased the analgesic potency of systemic, ICV and IT morphine; and the ICV and IT analgesic effects of the delta selective peptide, [D-Pen2,D-Pen5]enkephalin (DPDPE). Cocaine also increased the analgesic potency of the mu selective ligand [D-Ala2,NMePhe4,Gly-ol5]enkephalin (DAGO) administered ICV. However, cocaine did not alter the ED50 for IT DAGO. GC-MS studies indicated that brain cocaine concentration was approximately 3.0 micrograms/g wet weight 45 min following s.c. administration. These results suggest that cocaine-induced increases in opioid analgesic potency are mediated at brain mu and delta receptors and spinal mu receptors. Furthermore, there might be functional differences between spinal and supraspinal sites at which DAGO produces analgesia.
Collapse
Affiliation(s)
- V Sierra
- Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY 1439
| | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
Alterations in brain opioid binding and opioid pharmacodynamics following chronic (8-day) naltrexone (NTX) treatment were determined in pertussis toxin (PTX)-treated mice. Intrathecal (IT) and intracerebroventricular (ICV) PTX produced a time-dependent, long-lasting inhibition of morphine (SC) analgesia without modifying basal nociception. Inhibition was maximal 16 days following PTX treatment, and was still observed at 40 days. Relative to placebo controls, NTX treatment produced supersensitivity to morphine analgesia in all control mice and in mice pretreated with PTX 1 day before NTX. Supersensitivity was not observed in 7-day PTX-pretreated mice. [3H][D-Ala2-D-Leu5]enkephalin ([3H]DADLE) and [3H][D-Ala2-MePhe4-Gly(ol)5]enkephalin ([3H]DAMGO) binding sites were increased by NTX treatment in saline- and PTX-pretreated groups. KDs were unchanged. These results indicate that PTX does not alter opioid antagonist-induced receptor upregulation. However, PTX treatment can diminish morphine potency in upregulated and control mice. Therefore, opioid analgesia in control and upregulated mice appears to be mediated by receptors linked to a common PTX-sensitive G-protein. Furthermore, in 7-day PTX-pretreated mice, NTX increased binding sites without altering morphine potency, which suggests that new binding sites can appear without being functionally coupled.
Collapse
Affiliation(s)
- S C Chang
- Department of Pharmaceutical Sciences, College of Pharmacy & Allied Health Professions, St. John's University, Queens, NY 11439
| | | | | | | |
Collapse
|
19
|
Abstract
The present study evaluates the effect of pertussis toxin (PTX) on morphine-induced analgesia and lethality. Mice were injected with 0.2 microgram PTX intracerebroventricularly (i.c.v.) and 0.2 micrograms PTX intrathecally (i.t.) or saline. Mice were tested for morphine-induced analgesia (tail flick) and lethality 16 days later; mice were also examined for pentobarbital-induced mortality. Morphine analgesic potency was decreased by approximately 4-fold in PTX-treated mice compared to controls. Conversely, the lethal potency of morphine was increased by 10-fold in PTX-treated mice compared to controls. PTX treatment did not alter the lethal potency of pentobarbital. Morphine-induced analgesia and lethality were dose-dependently antagonized by naloxone in both PTX and saline-treated groups. The results of this study suggest that morphine analgesia is mediated through PTX-sensitive G proteins. On the other hand, morphine-induced lethality appears to be limited by PTX-sensitive factor(s) since PTX treatment enhanced morphine's lethal potency. The increase in lethal potency of morphine may be due to unmasking of an excitatory opioid receptor mediated effect by PTX.
Collapse
Affiliation(s)
- K Lutfy
- College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY 11439
| | | | | | | | | | | |
Collapse
|
20
|
Abstract
Mice treated chronically with opioid antagonists have increased receptor density in brain and are supersensitive to the pharmacodynamic action of morphine. In the present study mice were implanted subcutaneously with naltrexone or placebo pellets for 8 days. During implantation mice received daily injections of morphine (100 or 250 mg/kg) or saline. Morphine analgesia was completely blocked in mice that were implanted with naltrexone at the low dose of morphine; while some analgesic action was observed at the higher dose. Mice implanted with placebo were analgesic following the daily morphine treatment. At the end of 8 days the pellets were removed and 24 h later some mice were tested for morphine analgesia while others were examined in binding studies. Naltrexone treatment increased [3H]naloxone, 3H[D-Ala2-D-Leu5]enkephalin (DADLE) and 3H[D-Ala2,NMePhe4,Gly-ol5]enkephalin (DAGO) binding compared to controls and increased the analgesic potency of morphine. Daily treatment with morphine did not alter brain opioid binding or naltrexone-induced receptor upregulation. Mice injected daily with morphine were significantly less sensitive to morphine (tolerant) than their respective saline control group for both the placebo and the naltrexone-treated groups. However, naltrexone-treated mice were more sensitive to morphine than placebo controls regardless of whether they were injected daily with morphine or not. These results indicate that if naltrexone-induced opioid receptor upregulation occurs in the presence of repeated agonist administration, the new binding sites mediate tolerance via desensitization to morphine.
Collapse
Affiliation(s)
- B C Yoburn
- Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY 11439
| | | | | |
Collapse
|
21
|
Abstract
Administration of morphine into the spinal intrathecal (i.t.) space produced dose-dependent analgesia in the mouse. At higher doses i.t. morphine induced seizures of the hindlimbs. Mice treated chronically with morphine (75 mg pellet, s.c.) for 72 h were tolerant to the analgesic effects of i.t. morphine, but not to the proconvulsant action. Spinal morphine analgesia was attenuated by naloxone, whereas i.t. morphine-induced seizures were not. These results indicate that spinal opioid receptors mediate analgesia but not seizures following i.t. morphine treatment in the mouse.
Collapse
Affiliation(s)
- B C Yoburn
- Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY 11439
| | | | | | | |
Collapse
|
22
|
Abstract
Mice treated for 72 hrs with morphine (subcutaneously implanted pellets) were tested with a variety of opioid receptor agonists to examine the development of tolerance and cross-tolerance to their analgesic action. The development of spinal and supraspinal tolerance following morphine treatment was evaluated by administering compounds systemically (sc), intrathecally (IT) and intracerebroventricularly (ICV). Following morphine treatment, tolerance to morphine analgesia was observed following IT, ICV and sc administration. Chronic morphine treatment also produced cross-tolerance to the analgesic effects of the selective delta opioid receptor agonist [D-Pen2, D-Pen5]enkephalin (DPDPE) following IT and ICV administration. However, morphine treatment selectively produced cross-tolerance to ICV [D-Ala2, NMePhe4, Gly-ol5]enkephalin (DAGO) (mu receptor agonist) analgesia, without altering IT DAGO analgesia. These results suggest that brain and spinal cord receptors mediating the effects of DAGO differ in terms of the development of cross-tolerance to morphine; and suggest that tolerance to systemic morphine may be due to changes in spinal delta and brain mu and delta receptor mechanisms.
Collapse
Affiliation(s)
- B C Yoburn
- Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY 11439
| | | | | | | |
Collapse
|
23
|
Abstract
Changes in specific brain opioid binding and opioid pharmacodynamics were determined in mice treated with the opioid antagonist naltrexone (subcutaneously implanted pellets) for 8 days. Chronic opioid antagonist treatment increased the number of binding sites (upregulation) for [3H]naloxone (+55%) and [3H][D-Ala2, D-Leu5]enkephalin (+41%) but did not alter the affinity of the ligands, as determined in saturation studies. Displacement studies of [3H]naloxone by morphine also indicated that there was no change in morphine's affinity. In vivo estimation of naloxone affinity (pA2), agreed with the in vitro results indicating that chronic naltrexone treatment did not alter naloxone affinity. Chronic naltrexone treatment (0.5, 1.0, 15.0 mg pellets) increased the analgesic potency of morphine (supersensitivity) in a dose-dependent manner, up to a maximal increase in relative potency of 1.8. However, in mice tested with the naltrexone pellets still implanted, the 15 mg naltrexone pellet was able to shift the dose-response function for morphine analgesia more than 300-fold. The lowest dose naltrexone pellet (0.5 mg), produced significant antagonism of morphine analgesia, but did not produce significant supersensitivity. Thus, supersensitivity and upregulation are not proportional to the degree of antagonism of opioid effects; and supersensitivity in the mouse is related to increased binding sites and not to changes in receptor affinity as determined by in vivo and in vitro methods.
Collapse
Affiliation(s)
- B C Yoburn
- College of Pharmacy, St. John's University, Jamaica, NY 11439
| | | | | |
Collapse
|
24
|
Abstract
Chronic systemic treatment with the opioid antagonist, naltrexone, increased the analgesic potency of intrathecally administered opioid agonists at spinal mu and delta receptors, but not at kappa receptors. These results indicate that, contrary to a previous report, opioid receptors in the spinal cord display up-regulation and supersensitivity and are no different in this regard from supraspinal receptors.
Collapse
Affiliation(s)
- B C Yoburn
- Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY 11439
| | | | | | | | | |
Collapse
|
25
|
Abstract
Mice of the Swiss-Webster strain obtained from two suppliers (Taconic, Charles River) were found to differ in their sensitivity to morphine. Mice from Taconic were approximately two-fold more sensitive to the analgesic and lethal effects of morphine compared to the Charles River mice. In a third strain, C3H/HEN, morphine was found to be more than 2.5 times more potent in producing analgesia than in the Charles River mice. Binding studies showed that the Taconic mice and C3H/HEN mice had approximately 40% and 60%, respectively, more specific [3H]naloxone binding sites in brain than did the less sensitive Charles River mice. When treated with chronic naltrexone for 8 days the analgesic potency of morphine was increased by approximately 90% for both Swiss-Webster mice and by 20% for the C3H/HENs. [3H]Naloxone binding was increased by 45-50% in the Swiss-Webster strains, but by only 33% in C3H/HEN mice. These data indicate that receptor upregulation is directly related to increases in morphine potency. Further, these findings suggest that initial sensitivity to morphine can determine the degree of functional supersensitivity and relative receptor upregulation produced by chronic opioid antagonist treatment.
Collapse
Affiliation(s)
- B C Yoburn
- Department of Pharmaceutical Sciences, College of Pharmacy & Allied Health Professions, St. John's University, Jamaica, NY 11439
| | | | | | | |
Collapse
|
26
|
Abstract
The binding of [3H]5-hydroxytryptamine ([3H]5-HT) to cortical membranes was examined in female rats during diestrus, proestrus and estrus. Serotonin binding was lowest during the early afternoon of proestrus and highest during the afternoon of estrus with diestrous values in between. The high estrous values were associated with a significant increase in Bmax and a decrease in Kd. However, the increase in binding actually took place during the late afternoon of proestrus, when there was a rapid increase in binding from noon to 18.00 h. Binding remained at this elevated level throughout the next day. There were no changes in the binding of [3H]ketanserin or [3H]spiroperidol to cortical membranes during the estrous cycle, so the differential binding of [3H]5-HT is most likely the result of variations in 5-HT1 rather than 5-HT2 receptors. These observations of changes in serotonin binding in a brain area nearly devoid of sex steroid receptors suggest that the hormonal fluctuations accompanying the female estrous cycle influence brain areas other than those classically thought to regulate neuroendocrine function.
Collapse
|